Suven Pharmaceuticals, a leading contract development and manufacturing organization (CDMO), has received approval from the National Company Law Tribunal (NCLT) for its merger with Cohance Lifesciences. The ruling, issued on March 27, 2025, paves the way for the amalgamation to take effect once all necessary regulatory conditions are met, including approvals from the Department of Pharmaceuticals where applicable. The final implementation date will be disclosed to stock exchanges as per regulations, with completion expected by Q1 FY26.

This merger is set to establish a diversified CDMO platform with a strong technological foundation across three high-growth areas: antibody-drug conjugates (ADCs), oligonucleotides, and small molecules. The newly formed entity will serve as an integrated partner for global pharmaceutical innovators, offering enhanced scale, expanded customer solutions, and improved operational efficiency.

Vivek Sharma, Executive Chairman of Suven Pharmaceuticals, emphasized that this milestone strengthens their global presence, particularly in the specialized ADC sector, positioning the company toward achieving $1 billion in revenue within five years. Dr. V Prasada Raju, Managing Director, highlighted the strategic advantages of this merger in fostering innovation-led growth, particularly in the specialty CDMO and API+ segments, enabling the company to deliver impactful pharmaceutical solutions while driving long-term value creation.